For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | - | - | - | 2,996 |
| Research and development | 2,239 | 4,739 | 4,156 | 7,113 |
| General and administrative | 5,314 | 2,550 | 3,432 | 3,306 |
| Total cost and expenses | 7,553 | 7,289 | 7,588 | 10,419 |
| Operating loss | -7,553 | -7,289 | -7,588 | -7,423 |
| Interest income | 537 | 607 | 713 | 940 |
| Interest expense | - | - | 129 | 129 |
| Gain on extinguishment of borrowings | - | - | 5,203 | - |
| Foreign currency exchange (loss) gain, net | -166 | -1,885 | -1,453 | 492 |
| Total other income (expense), net | 371 | -1,278 | 4,334 | 1,302 |
| Net loss before taxes | -7,182 | -8,567 | -3,254 | -6,121 |
| Income tax expense | 6 | 72 | 225 | 158 |
| Net loss | -7,188 | -8,639 | -3,479 | -6,278 |
| Foreign currency translation adjustment | -456 | 2,349 | 978 | -439 |
| Comprehensive loss | -7,644 | -6,290 | -2,501 | -6,718 |
| Earnings per share, basic | -0.27 | -0.32 | -0.13 | -0.235 |
| Earnings per share, diluted | -0.27 | -0.32 | -0.13 | -0.235 |
| Weighted average number of shares outstanding, basic | 26,899,122 | 26,899,122 | 26,892,575 | 6,708,605.5 |
| Weighted average number of shares outstanding, diluted | 26,899,122 | 26,899,122 | 26,892,575 | 6,708,605.5 |
LAVA Therapeutics NV (LVTX)
LAVA Therapeutics NV (LVTX)